免疫剂量和途径对异源卡介苗初免及重组腺病毒载体加强免疫诱导牛免疫反应的影响

Effect of dose and route of immunisation on the immune response induced in cattle by heterologous Bacille Calmette-Guerin priming and recombinant adenoviral vector boosting.

作者信息

Dean G, Clifford D, Gilbert S, McShane H, Hewinson R G, Vordermeier H M, Villarreal-Ramos B

机构信息

Bovine TB, AHVLA-Weybridge, New Haw, Addlestone, Surrey KT15 3NB, UK.

The Jenner Institute Old Road Campus Research Building Oxford University, Roosevelt Drive, Oxford OX3 7DQ, UK.

出版信息

Vet Immunol Immunopathol. 2014 Apr 15;158(3-4):208-13. doi: 10.1016/j.vetimm.2014.01.010. Epub 2014 Jan 28.

DOI:10.1016/j.vetimm.2014.01.010

PMID:24581917

Abstract

BCG is used experimentally as a vaccine against tuberculosis (TB), induced by Mycobacterium bovis, in cattle (bTB). However, the efficacy of BCG is variable in humans, cattle and guinea pigs. An adenoviral vector expressing Antigen 85A (Ad5Ag85A) has enhanced protection against TB in mice when used in combination with BCG for prime-boost experiments. However, the route of immunisation affects the degree of protection seen. This work examines the immunogenicity of a new vectored vaccine (Ad5-TBF) that expresses Ag85A, Rv0287, Rv0288 and Rv0251c to explore the effects of dose of adenoviral boost and route of inoculation on immunogenicity. We found that 2×10(9) infectious units (iu) delivered intradermally conferred the most consistent and strongest responses of the different regimes tested.

摘要

卡介苗（BCG）在实验中用作牛结核病（bTB）的疫苗，牛结核病由牛分枝杆菌引起。然而，卡介苗在人类、牛和豚鼠中的疗效存在差异。在小鼠中，当将表达85A抗原的腺病毒载体（Ad5Ag85A）与卡介苗联合用于初次-加强实验时，可增强对结核病的保护作用。然而，免疫途径会影响所观察到的保护程度。这项工作研究了一种新的载体疫苗（Ad5-TBF）的免疫原性，该疫苗表达Ag85A、Rv0287、Rv0288和Rv0251c，以探讨腺病毒加强剂量和接种途径对免疫原性的影响。我们发现，皮内注射2×10⁹感染单位（iu）在不同测试方案中产生的反应最一致且最强。